Cannapharmarx Depreciation & Amortization Growth & History (CPMD)
Cannapharmarx's depreciation and amortization was $0 for fiscal 2024.
View full Cannapharmarx company overviewCannapharmarx annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $0 | −$127,847 | — |
| 2023 | 2023-12-31 | $127,847 | −$167,087 | −56.65% |
| 2022 | 2022-12-31 | $294,934 | $292,226 | +10791.21% |
| 2021 | 2021-12-31 | $2,708 | −$125,797 | −97.89% |
| 2020 | 2020-12-31 | $128,505 | −$530 | −0.41% |
| 2019 | 2019-12-31 | $129,035 | $129,035 | — |
| 2018 | 2018-12-31 | $0 | $0 | — |
| 2017 | 2017-12-31 | $0 | $0 | — |
| 2016 | 2016-12-31 | $0 | −$12,031 | — |
| 2015 | 2015-12-31 | $12,031 | $12,031 | — |
| 2014 | 2014-12-31 | $0 | — | — |
Cannapharmarx quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $15,808 | $15,808 | — |
| Q3 2025 | 2025-09-30 | $0 | $0 | — |
| Q2 2025 | 2025-06-30 | $0 | −$64,237 | — |
| Q1 2025 | 2025-03-31 | $0 | −$23,041 | — |
| Q4 2024 | 2024-12-31 | −$87,278 | — | — |
| Q3 2024 | 2024-09-30 | $0 | −$76,550 | — |
| Q2 2024 | 2024-06-30 | $64,237 | −$9,718 | −13.14% |
| Q1 2024 | 2024-03-31 | $23,041 | $17,215 | +295.49% |
| Q3 2023 | 2023-09-30 | $76,550 | $577 | +0.76% |
| Q2 2023 | 2023-06-30 | $73,955 | $2,402 | +3.36% |
| Q1 2023 | 2023-03-31 | $5,826 | −$68,238 | −92.13% |
| Q3 2022 | 2022-09-30 | $75,973 | $75,211 | +9870.21% |
| Q2 2022 | 2022-06-30 | $71,553 | $70,777 | +9120.75% |
| Q1 2022 | 2022-03-31 | $74,064 | $73,656 | +18052.94% |
| Q3 2021 | 2021-09-30 | $762 | −$35,546 | −97.90% |
| Q2 2021 | 2021-06-30 | $776 | −$30,701 | −97.53% |
| Q1 2021 | 2021-03-31 | $408 | −$31,256 | −98.71% |
| Q3 2020 | 2020-09-30 | $36,308 | $4,086 | +12.68% |
| Q2 2020 | 2020-06-30 | $31,477 | −$310 | −0.98% |
| Q1 2020 | 2020-03-31 | $31,664 | −$336 | −1.05% |
| Q3 2019 | 2019-09-30 | $32,222 | $32,222 | — |
| Q2 2019 | 2019-06-30 | $31,787 | $31,787 | — |
| Q1 2019 | 2019-03-31 | $32,000 | $32,000 | — |
| Q3 2018 | 2018-09-30 | $0 | $0 | — |
| Q2 2018 | 2018-06-30 | $0 | $0 | — |
| Q1 2018 | 2018-03-31 | $0 | $0 | — |
| Q3 2017 | 2017-09-30 | $0 | $0 | — |
| Q2 2017 | 2017-06-30 | $0 | $0 | — |
| Q1 2017 | 2017-03-31 | $0 | $0 | — |
| Q3 2016 | 2016-09-30 | $0 | −$3,192 | — |
| Q2 2016 | 2016-06-30 | $0 | −$3,192 | — |
| Q1 2016 | 2016-03-31 | $0 | −$3,135 | — |
| Q3 2015 | 2015-09-30 | $3,192 | $3,192 | — |
| Q2 2015 | 2015-06-30 | $3,192 | $3,192 | — |
| Q1 2015 | 2015-03-31 | $3,135 | $3,135 | — |
| Q3 2014 | 2014-09-30 | $0 | — | — |
| Q2 2014 | 2014-06-30 | $0 | — | — |
| Q1 2014 | 2014-03-31 | $0 | — | — |
Cannapharmarx depreciation and amortization trends
Over the last five fiscal years, Cannapharmarx's depreciation and amortization decreased from $129,035 to $0, a change of −$129,035. The latest reported quarter, Q2 2026, shows $0.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cannapharmarx source filings ↗